Diabetes and cancer: two diseases with obesity as a common risk factor

Abstract

There is a growing body of evidence to support a connection between diabetes (predominantly type 2), obesity and cancer. Multiple meta‐analyses of epidemiological data show that people with diabetes are at increased risk of developing many different types of cancers, along with an increased risk of cancer mortality. Several pathophysiological mechanisms for this relationship have been postulated, including insulin resistance and hyperinsulinaemia, enhanced inflammatory processes, dysregulation of sex hormone production and hyperglycaemia. In addition to these potential mechanisms, a number of common risk factors, including obesity, may be behind the association between diabetes and cancer. Indeed, obesity is associated with an increased risk of cancer and diabetes. Abdominal adiposity has been shown to play a role in creating a systemic pro‐inflammatory environment, which could result in the development of both diabetes and cancer. Here, we examine the relationship between diabetes, obesity and cancer, and investigate the potential underlying causes of increased cancer risk in individuals with diabetes. Current treatment recommendations for reducing the overall disease burden are also explored and possible areas for future research are considered.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 177

1. 1.

   Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757.

   Not in our library10.1016/s0140-6736(06)68770-9

2. 2.

   Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369-2380.

   Not in our library10.1016/j.ejca.2010.06.012

3. 3.

   Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674-1685.

   Not in our library10.2337/dc10-0666

4. 4.

   Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia. 2010;53:2086-2088.

   Not in our library10.1007/s00125-010-1855-0

5. 5.

   LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes. 2008;116(Suppl. 1):S4-S6.

   Not in our library10.1055/s-2008-1081488

6. 6.

   Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732-1744.

   Not in our library10.1007/s00125-009-1418-4

7. 7.

   Bowker SL, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254-258.

   Not in our library10.2337/diacare.29.02.06.dc05-1558

8. 8.

   Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766-1777.

   Not in our library10.1007/s00125-009-1440-6

9. 9.

   Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745-1754.

   Not in our library10.1007/s00125-009-1444-2

10. 10.

    Boyle P. Northern European Database Study of Insulin and Cancer Risk. 2012.

    Not in our library

11. 11.

    Habel LA. Results from Kaiser-Permanente Collaboration. 2012.

    Not in our library

12. 12.

    Sturmer T. Cancer link with insulin-data from the U.S. and Northern Europe. 2012.

    Not in our library

13. 13.

    Boyle P, Koechlin A, Bonio M, Robertson C, Bolli G, Rosenstock J. Updated meta-analysis of cancer risk among users of insulin glargine. 2012.

    Not in our library

14. 14.

    Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.

    Not in our library10.1056/nejmoa1203858

15. 15.

    Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 2003;26:1752-1758.

    Not in our library10.2337/diacare.26.6.1752

16. 16.

    Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542-547.

    Not in our library10.1093/jnci/91.6.542

17. 17.

    Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology. 2010;139:1138-1146.

    Not in our library10.1053/j.gastro.2010.06.072

18. 18.

    Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16:276-280.

    Not in our library10.1158/1055-9965.epi-06-0751

19. 19.

    Parazzini F, La Vecchia C, Negri E, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer. 1999;81:539-542.

    Not in our library10.1002/(sici)1097-0215(19990517)81:4<539::aid-ijc6>3.0.co;2-q

20. 20.
    Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer · 1999

    No notice
21. 21.

    Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CWJR. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9:403-410.

    Not in our library10.1023/a:1008819701485

22. 22.

    Ben Q, Cai Q, Li Z, et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer. 2011;47:248-254.

    Not in our library10.1016/j.ejca.2010.07.010

23. 23.

    Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49:2819-23.

    Not in our library10.1007/s00125-006-0468-0

24. 24.

    Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121:856-862.

    Not in our library10.1002/ijc.22717

25. 25.

    Wolf I, Sadetzki S, Gluck I, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006;42:1077-1082.

    Not in our library10.1016/j.ejca.2006.01.027

26. 26.

    Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97:1679-1687.

    Not in our library10.1093/jnci/dji375

27. 27.

    Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol. 2005;6:103-111.

    Not in our library10.1016/s1470-2045(05)01736-5

28. 28.

    Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50:1365-1374.

    Not in our library10.1007/s00125-007-0681-5

29. 29.

    El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-380.

    Not in our library10.1016/j.cgh.2005.12.007

30. 30.

    Mitri J, Castillo J, Pittas AG. Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies. Diabetes Care. 2008;31:2391-2397.

    Not in our library10.2337/dc08-1034

31. 31.

    Chao C, Page JH. Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. Am J Epidemiol. 2008;168:471-480.

    Not in our library10.1093/aje/kwn160

32. 32.

    Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273:1605-1609.

    Not in our library

33. 33.
    Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies · 2005

    No notice
34. 34.

    Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071-1078.

    Not in our library10.1007/s00125-004-1415-6

35. 35.

    Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:2056-2062.

    Not in our library10.1158/1055-9965.epi-06-0410

36. 36.

    Johnson JA, Carstensen B, Witte D, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55:1607-1618.

    Not in our library10.1007/s00125-012-2525-1

37. 37.

    Turner EL, Lane JA, Donovan JL, et al. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer. 2011;128:440-446.

    Not in our library10.1002/ijc.25360

38. 38.

    Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16:151-158.

    Not in our library10.1038/pcan.2012.40

39. 39.

    Pierce BL. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol. 2012;30:735-743.

    Not in our library10.1016/j.urolonc.2012.07.008

40. 40.

    Liu JH, Li HW, Tong M, Li M, Na YQ. Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer. Zhonghua Yi Xue Za Zhi. 2004;84:364-8.

    Not in our library

Cited by papers we hold 4

• Decreased IGF-1 level is associated with restrained amino acid metabolism in NSCLC with diabetes mellitus · 2022
  Not checked
• Effects of hyperglycemia on the progression of tumor diseases · 2019
  No notice
• Adipose Tissue-Derived Signatures for Obesity and Type 2 Diabetes: Adipokines, Batokines and MicroRNAs · 2019
  No notice
• α-Glucosidase inhibition by flavonoids: an in vitro and in silico structure–activity relationship study · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.